title: Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
abstract: Research in the past 2 decades showed that attention-deficit/hyperactivity disorder (ADHD) is a frequently occurring psychiatric disorder that causes considerable suffering to patients and their families. This article outlines current pharmacologic ADHD treatment options and focuses on their safety profile and efficacy. In addition, it addresses treatment selection, guidelines for monitoring treatment, and recent controversies in the field.
authors.affiliation: Department of Psychiatry, Hoboken University Medical Center, Hoboken, NJ 07030, USA. drgkaplan@gmail.com
authors.forename: Gabriel
authors.initials: G
authors.lastname: Kaplan
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Newcorn
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D058647:Adrenergic alpha-2 Receptor Agonists / Q000627:therapeutic use; D000662:Amphetamines / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D016316:Guanfacine / Q000627:therapeutic use; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use; D011437:Propylamines / Q000627:therapeutic use
chemical_list: D018759:Adrenergic Uptake Inhibitors; D058647:Adrenergic alpha-2 Receptor Agonists; D000662:Amphetamines; D000697:Central Nervous System Stimulants; D011437:Propylamines; D008774:Methylphenidate; D016316:Guanfacine; D000069445:Atomoxetine Hydrochloride